

# **Asia-Pacific Anti-Inflammatory Therapeutics Market by Indication [Arthritis, Respiratory Disease, Multiple Sclerosis, Psoriasis, and Inflammatory Bowel Disease (IBD)], by Drug Class [Nonsteroidal Anti-Inflammatory Diseases (NSAIDs), Corticosteroids, Biologics, and Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)]: Asia-Pacific Opportunity Analysis and Industry Forecast, 2015-2020**

<https://marketpublishers.com/r/A1044808479EN.html>

Date: June 2015

Pages: 130

Price: US\$ 3,999.00 (Single User License)

ID: A1044808479EN

## **Abstracts**

The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Moreover, increasing awareness of anti-inflammatory biologics and favorable government initiatives in the Asia-Pacific region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and uncertain patent legislations, i.e., compulsory licensing in India would continue to impede the market growth.

The industry is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis was the dominant segment accounting for 41.3% of the APAC anti-inflammatory therapeutics market in 2014 and holds potential for growth during the forecast period. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis.

On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for around 50% share of the market, and is expected to grow rapidly during the forecast period. Geographically, the market is segmented into six countries namely Japan, China, India, Australia, South Korea, Indonesia and others. Among these countries, Japan holds the largest share in the industry; however, China is expected to exhibit the fastest growth during the forecast period. Major market players have adopted strategies such as collaborations, indication expansions and product launches to expand their market presence. In 2014, Novartis got marketing approval for the drug Cosentyx (secukinumab) in Japan for the treatment of psoriatic arthritis. The company has filed new patents to overcome the issues of patent expiries of their existing drugs and to gain a prominent market share. The key companies profiled in this report are Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc., Novartis AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, AstraZeneca PLC and Amgen.

## **KEY BENEFITS**

The report provides a quantitative analysis of the current market and estimations during 2014-2020 that assist in identifying and capitalizing on the prevailing market opportunities

Exhaustive analysis of the market by product type helps in understanding the types of therapeutics and their categories that are currently being used to gain prominence in future

Competitive intelligence of leading manufacturers and distributors of anti-inflammatory therapeutics helps in understanding the competitive scenario across the geographies

Comprehensive analysis of factors that drive and restrict the growth of the industry has been provided

SWOT analysis facilitates the study of internal environment of leading companies for strategic decision-making

The country-wise analyses of market conditions have been provided in this report

## KEY MARKET SEGMENTS

The Asia-Pacific Anti-inflammatory Therapeutics Market is segmented below:

### BY INDICATION

- Arthritis
- Respiratory diseases
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Other inflammatory diseases

### BY DRUG CLASS

- Anti-Inflammatory Biologics
- Non-Steroidal Anti-inflammatory drugs (NSAIDs)
- Corticosteroids

### BY GEOGRAPHY

- Japan
- China
- India
- Australia
- South Korea
- Indonesia

Other APAC countries

## Contents

### CHAPTER 1 INTRODUCTION

- 1.1 Report Description
- 1.2 Key Market Benefits
- 1.3 Key Market Segments
- 1.4 Research methodology
  - 1.4.1 Secondary research
  - 1.4.2 Primary research
  - 1.4.3 Analyst tools and models

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 CXO perspective

### CHAPTER 3 MARKET OVERVIEW

- 3.1 Market definition and scope
- 3.2 Key findings
  - 3.2.1 Top impacting factors
  - 3.2.2 Top investment pockets
  - 3.2.3 Top winning strategies
- 3.3 Government Regulations
- 3.4 Reimbursement Scenario
- 3.5 Porters Five Force Analysis
  - 3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
  - 3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
  - 3.5.3 High capital investment and patent provision lowers the threats from new entrants
  - 3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
  - 3.5.5 Industry rivalry is low to moderate due to presence of few competitors
- 3.6 Value chain analysis
- 3.7 Clinical Trials
- 3.8 Patent Analysis
- 3.9 Market Share Analysis, (2014)
- 3.10 Market dynamics

### 3.10.1 Drivers

3.10.1.1 Rising incidences of autoimmune and respiratory conditions:

3.10.1.2 New Drugs in Pipeline

3.10.1.3 Increasing adoption rate of anti-inflammatory drugs

### 3.10.2 Restraints

3.10.2.1 Side Effects of Anti-Inflammatory Drugs

3.10.2.2 Patent expirations

### 3.10.3 Opportunities

3.10.3.1 Developing biosimilars for the existing drugs

3.10.3.2 Tapping the emerging markets in developing regions

## **CHAPTER 4 BY INDICATION**

### 4.1 Arthritis

4.1.1 Market size and forecast

4.1.2 Rheumatoid Arthritis

4.1.3 Osteoarthritis

4.1.4 Ankylosing Spondylitis

4.1.5 Psoriatic Arthritis

4.1.6 Gout

### 4.2 Respiratory Diseases

4.2.1 Market size and forecast

4.2.2 Asthma

4.2.3 Chronic obstructive pulmonary disease (COPD)

### 4.3 Multiple Sclerosis

4.3.1 Market size and forecast by region

### 4.4 Psoriasis

4.4.1 Market size and forecast

### 4.5 Inflammatory Bowel Disease (IBD)

4.5.1 Market size and forecast

4.5.2 Crohns Disease

4.5.3 Ulcerative Colitis

### 4.6 Other Inflammatory Diseases

4.6.1 Market size and forecast

## **CHAPTER 5 BY DRUG CLASS**

### 5.1 Anti-inflammatory Biologics

5.1.1 Key Market Trends

- 5.1.2 Market Growth factors and opportunities
- 5.1.3 Market size and forecast
- 5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  - 5.2.1 Key Market Trends
  - 5.2.2 Market growth factors and opportunities
  - 5.2.3 Market size and forecast
- 5.3 Corticosteroids
  - 5.3.1 Key Market Trends
  - 5.3.2 Market Growth factors and opportunities
  - 5.3.3 Market size and forecast
- 5.4 Other anti-inflammatory drugs

## **CHAPTER 6 BY COUNTRY**

- 6.1 Key market trends
- 6.2 Key growth factors and opportunities
  - 6.2.1 Market size and forecast
- 6.3 Japan
  - 6.3.1 Key market trends
  - 6.3.2 Key growth factors and opportunities
  - 6.3.3 Market size and forecast
- 6.4 China
  - 6.4.1 Key market trends
  - 6.4.2 Key growth factors and opportunities
  - 6.4.3 Market size and forecast
- 6.5 India
  - 6.5.1 Key market trends
  - 6.5.2 Key growth factors and opportunities
  - 6.5.3 Market size and forecast
- 6.6 Australia
  - 6.6.1 Key market trends
  - 6.6.2 Key growth factors and opportunities
  - 6.6.3 Market size and forecast
- 6.7 South Korea
  - 6.7.1 Key market trends
  - 6.7.2 Key growth factors and opportunities
  - 6.7.3 Market size and forecast
- 6.8 Indonesia
  - 6.8.1 Key market trends

- 6.8.2 Key growth factors and opportunities
- 6.8.3 Market size and forecast
- 6.9 Rest of Asia Pacific

## **CHAPTER 7 COMPANY PROFILES**

- 7.1 Pfizer Inc.
  - 7.1.1 Company overview
  - 7.1.2 Company snapshot
  - 7.1.3 Business performance
  - 7.1.4 Strategic moves and developments
  - 7.1.5 SWOT analysis & strategic conclusions
- 7.2 AbbVie Inc.
  - 7.2.1 Company overview
  - 7.2.2 Company snapshot
  - 7.2.3 Business performance
  - 7.2.4 Strategic Moves and Developments
  - 7.2.5 SWOT analysis & strategic conclusions
- 7.3 Johnson & Johnson
  - 7.3.1 Company overview
  - 7.3.2 Company snapshot
  - 7.3.3 Business performance
  - 7.3.4 Strategic Moves and Developments
  - 7.3.5 SWOT analysis & strategic conclusions
- 7.4 GlaxoSmithKline plc
  - 7.4.1 Company Overview
  - 7.4.2 Company snapshot
  - 7.4.3 Business performance:
  - 7.4.4 Strategic moves and developments
  - 7.4.5 SWOT analysis & strategic conclusions
- 7.5 Merck & Co., Inc.
  - 7.5.1 Company overview
  - 7.5.2 Company snapshot
  - 7.5.3 Business Performance
  - 7.5.4 Strategic Moves and Developments
  - 7.5.5 SWOT analysis and strategic conclusions
- 7.6 Novartis AG
  - 7.6.1 Company overview
  - 7.6.2 Company snapshot



- 7.6.3 Business Performance
- 7.6.4 Strategic moves and developments
- 7.6.5 SWOT analysis and strategic conclusions
- 7.7 F. Hoffmann-La Roche AG
  - 7.7.1 Company profile
  - 7.7.2 Company snapshot
  - 7.7.3 Business Performance
  - 7.7.4 Strategic moves and developments
  - 7.7.5 SWOT analysis and strategic conclusions
- 7.8 Eli Lilly and Company
  - 7.8.1 Company overview
  - 7.8.2 Company snapshot
  - 7.8.3 Business performance
  - 7.8.4 Strategic Moves and Developments
  - 7.8.5 SWOT analysis and strategic conclusions
- 7.9 AstraZeneca PLC.
  - 7.9.1 Company overview
  - 7.9.2 Company snapshot
  - 7.9.3 Business performance
  - 7.9.4 Strategic Moves and Developments
  - 7.9.5 SWOT analysis and strategic conclusions
- 7.10 Amgen Inc.
  - 7.10.1 Company overview
  - 7.10.2 Company snapshot
  - 7.10.3 Business performance
  - 7.10.4 Strategic Moves and Developments
  - 7.10.5 SWOT analysis and strategic conclusions

## List Of Tables

### LIST OF TABLES

TABLE 1 CLINICAL TRIALS FOR ANTI-INFLAMMATORY DRUGS

TABLE 2 PATENT EXPIRY OF MAJOR BRANDS

TABLE 3 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, (\$MILLION)

TABLE 4 ASIA-PACIFIC ARTHRITIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 5 ASIA-PACIFIC RESPIRATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 6 ASIA-PACIFIC MULTIPLE SCLEROSIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 7 ASIA-PACIFIC PSORIASIS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 8 ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 9 ASIA-PACIFIC OTHER INFLAMMATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 10 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 (\$MILLION)

TABLE 11 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 (\$MILLION)

TABLE 12 ASIA-PACIFIC ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 13 ASIA-PACIFIC NSAIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 14 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 (\$MILLION)

TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 (\$MILLION)

TABLE 16 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014 2020 (\$MILLION)

TABLE 17 JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 (\$MILLION)

TABLE 18 CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 (\$MILLION)

TABLE 19 INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG

CLASS, 2014 2020 (\$MILLION)

TABLE 20 AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 (\$MILLION)

TABLE 21 SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 (\$MILLION)

TABLE 22 INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 (\$MILLION)

TABLE 23 REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 (\$MILLION)

TABLE 24 PFIZER INC SNAPSHOT

TABLE 25 ABBVIE INC. SNAPSHOT

TABLE 26 JOHNSON & JOHNSON SNAPSHOT

TABLE 27 GLAXOSMITHKLINE SNAPSHOT

TABLE 28 MERCK & CO SNAPSHOT

TABLE 29 NOVARTIS AG SNAPSHOT

TABLE 30 F. HOFFMANN-LA ROCHE AG SNAPSHOT

TABLE 31 ELI LILLY SNAPSHOT

TABLE 32 ASTRAZENECA SNAPSHOT

TABLE 33 AMGEN INC SNAPSHOT

## List Of Figures

### LIST OF FIGURES

- FIG. 1 TYPES OF ANTI-INFLAMMATORY THERAPEUTICS
- FIG. 2 TOP FACTORS IMPACTING ON ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
- FIG. 3 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
- FIG. 4 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICS MARKET (2012-2015)
- FIG. 5 PORTER'S FIVE FORCES ANALYSIS
- FIG. 6 VALUE CHAIN OF ANTI-INFLAMMATORY THERAPEUTICS MARKET
- FIG. 7 MARKET SHARE ANALYSIS, (2014)
- FIG. 8 PFIZER FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
- FIG. 9 PFIZER FINANCIAL REVENUES BY GEOGRAPHY (2014)
- FIG. 10 PFIZER FINANCIAL REVENUES BY YEAR (\$MILLION)
- FIG. 11 PFIZER SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 12 ABBVIE, INC. FINANCIAL REVENUES BY YEAR (\$MILLION)
- FIG. 13 HUMIRA FINANCIAL REVENUES BY YEAR (\$MILLION)
- FIG. 14 ABBVIE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 15 JOHNSON & JOHNSON PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
- FIG. 16 JOHNSON & JOHNSON SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 17 GLAXOSMITHKLINE FINANCIAL REVENUES BY GEOGRAPHY (2014)
- FIG. 18 GLAXOSMITHKLINE FINANCIAL REVENUES BY THERAPY AREA
- FIG. 19 GLAXOSMITHKLINE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 20 MERCK FINANCIAL REVENUES BY YEAR (\$MILLION)
- FIG. 21 MERCK FINANCIAL REVENUES BY GEOGRAPHY (2014)
- FIG. 22 MERCK SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 23 NOVARTIS FINANCIAL REVENUES BY GEOGRAPHY (2014)
- FIG. 24 NOVARTIS FINANCIAL REVENUES BY SEGMENT (2014)
- FIG. 25 NOVARTIS SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 26 ROCHE FINANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
- FIG. 27 ROCHE FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
- FIG. 28 ROCHE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
- FIG. 29 ELI LILLY FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
- FIG. 30 ELI LILLY SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
- FIG. 31 ASTRAZENECA FINANCIAL REVENUES BY GEOGRAPHY (2014)

- FIG. 32 ASTRAZENECA FINANCIAL REVENUES BY YEAR (\$MILLION)
- FIG. 33 ASTRAZENECA SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
- FIG. 34 AMGEN FINANCIAL REVENUES BY PRODUCT (2014)
- FIG. 35 AMGEN FINANCIAL REVENUES BY YEAR (\$MILLION)
- FIG. 36 AMGEN SWOT ANALYSIS AND STRATEGIC CONCLUSIONS

## I would like to order

Product name: Asia-Pacific Anti-Inflammatory Therapeutics Market by Indication [Arthritis, Respiratory Disease, Multiple Sclerosis, Psoriasis, and Inflammatory Bowel Disease (IBD)], by Drug Class [Nonsteroidal Anti-Inflammatory Diseases (NSAIDs), Corticosteroids, Biologics, and Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)]: Asia-Pacific Opportunity Analysis and Industry Forecast, 2015-2020

Product link: <https://marketpublishers.com/r/A1044808479EN.html>

Price: US\$ 3,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1044808479EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970